Mereo BioPharma Group plc
Mereo BioPharma Group plc (MREO): 6 pipeline candidates · ~17 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
16.5 months
D/E 0.12
Lead: Phase 3
6 candidates
N/A
N/A
A transparent, data-derived signal for Mereo BioPharma Group plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$48.7M
Cash
$41.0M
Quarterly Burn
$4.2M
Runway
16.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| alvelestat | Phase 3 |
| etigilimab | Phase 1 |
| leflutrozole | Phase 2 |
| navicixizumab | Phase 1 |
| setrusumab | Phase 3 |
| vantictumab | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
58
Total value held
$11.7M
| Holder | Shares | Value |
|---|---|---|
| 683 capital management, llc | 12,000,000 | $4.0M |
| bank of america corp /de/ | 8,195,287 | $2.7M |
| newtyn management, llc | 7,079,056 | $2.3M |
| millennium management llc | 3,559,103 | $1.2M |
| marshall wace, llp | 686,987 | $227K |
| citadel advisors llc | 454,800 | $150K |
| susquehanna international group, llp | 443,920 | $146K |
| group one trading llc | 335,827 | $111K |
| jane street group, llc | 333,773 | $110K |
| rangeley capital, llc | 329,200 | $109K |
Showing top 10 of 58 institutional holders of Mereo BioPharma Group plc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Mereo BioPharma Group plc's pipeline?
Mereo BioPharma Group plc (MREO) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Mereo BioPharma Group plc's lead drug candidate?
Mereo BioPharma Group plc's most advanced tracked candidate is alvelestat (Phase 3) for Severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
What is Mereo BioPharma Group plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Mereo BioPharma Group plc has approximately 16.5 months of cash runway.
What is Mereo BioPharma Group plc's market capitalization?
Mereo BioPharma Group plc's market capitalization is approximately $48.7M.
Who is the CEO of Mereo BioPharma Group plc?
Dr. Denise Vera Scots-Knight Ph.D. is the chief executive officer of Mereo BioPharma Group plc (MREO).
Get the full picture on Mereo BioPharma Group plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.